Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Selcia Granted Patent for CEfrag™ Drug Discovery Platform

Published: Friday, September 21, 2012
Last Updated: Friday, September 21, 2012
Bookmark and Share
CEfrag™ platform uses capillary electrophoresis to identify fragment compounds.

Selcia Limited has been granted a UK patent for the technology platform underpinning the company’s CEfrag™ drug screening service.

Titled “Capillary electrophoresis method for assessing the binding of chemical compounds to biological targets”, the patent relates to the screening of compound libraries against specific targets, in particular screening for weak-binding ligands.

Numbered GB 2481168, the patent was filed 20 September 2010 and granted 27 June 2012.

The patenting of Selcia’s CEfrag technology is the culmination of a three year plan by Selcia to build a fully integrated drug discovery division alongside its existing 14C radiochemistry service.

The newly patented technology was first unveiled by Selcia following the acquisition of IP and expertise from Cetek Corporation in 2009.

Further technical development of the fragment screening platform resulted in the launch of CEfrag the following year with a fragment library of 1,500 compounds.

CEfrag has generated a great deal of interest amongst pharmaceutical and biotech organizations and this has already resulted in a number of collaborations including a recent deal with Heptares, a UK-based biotech company that discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors) The goal of this collaboration was to identify fragment ligands that specifically bind to a Heptares GPCR drug target.

Selcia’s CEfrag™ platform uses capillary electrophoresis to identify fragment compounds that selectively bind to drug targets.

A significant advantage of this approach is that all reagents are in solution and no tethering of the protein is required, enabling near physiological ligand/target interactions to be observed with a low false positive rate.

The technology can be used to detect fragment/target interactions across a wide range of target classes including “challenging” targets such as protein-protein interactions.

The technology can also be used to screen natural extracts for novel druggable natural compound starting points for drug discovery programmes, an area in which Selcia specializes.

Simon Bury, Business Development Director - Discovery, Selcia, comments: “The CEfrag drug screening platform has already shown itself to be a novel, scientifically robust approach to drug discovery. By patenting the technology we have demonstrated our strong intent to build a differentiated technology platform that will sit at the heart of Selcia’s integrated drug discovery service capabilities”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selcia Appoints New Director of Discovery
Appointment of John Davis to the role of Director of Discovery.
Wednesday, October 09, 2013
Selcia and Heptares Therapeutics Announce New Fragment Screening Collaboration
Partnership to utilize Selcia’s CEfrag™ capillary electrophoresis fragment screening technology.
Thursday, April 19, 2012
Scientific News
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Diagnostics Breakthrough Brings Viral Sequencing to Doctors’ Toolkit
New screening tool produces up to 10,000-fold improvement in viral matches compared with traditional high-throughput methods.
New Virus Identified In Blood Supply
Scientists have discovered a new virus that can be transmitted through the blood supply.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos